Supervisor Database Search
Search for supervisors below. You can filter your search using the options and select
multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year. You can read the ICAT supervisor policy here.
Full NameProfessor Elisabeth Vandenberghe
Haematology
Trinity College Dublin
Webpage:www.tcd.ie
Email Address:Email hidden; Javascript is required.
- genetics, genomics and molecular biology
- cancer/oncology
- clinical trials
- Medicine
- Pathology
- Haematology
My research interest in lymphoid malignancies is based on clinical trial involvement and translating molecular diagnostics into precision medicine pathways. I direct the Cancer Trials Unit (CTU) at St James Hospital (SJH) and am PI of 17 Phase II/III trials(5 open/12 completed) leading to 7 publications. I collaborate internationally with the European Mantle Cell Lymphoma (MCL) network and am on the lymphoma sub-group of the European Blood and Marrow Transplant (EBMT) and have co-authored 7 registry publications.
I direct the Cancer Molecular Diagnostic (CMD) laboratory at SJH which provides a national diagnostic service focussing on
(1) MCL including association with t(11;14) and treatment pathway incorporating transplantation, targeted therapy with ibrutinib and MRD-based treatment.
(2) Chronic lymphocytic leukaemia (CLL):I opened the only national multi-institutional phase II molecular and clinical trial, (published 2017). I collaborate with the European Research Initiative in CLL ‘big data’ project (submitting 140 genetically characterised cases). I am PI of a recruiting multi-institutional molecular epidemiology study of CLL.
(3) T lymphoid malignancies: the molecular diagnosis of T-large granular lymphocytic leukaemia and molecular analysis-based risk of coeliac disease transformation to lymphoma
I collaborate with Dr McElligott from Trinity Translational Medicine Institute (TTMI) who investigates cellular mechanisms of leukaemogenesis and new drug therapies and Professor Bracken (TCD) who leads an SFI-funded project ‘Understanding the role of EZH2 deregulation in B-Cell Lymphomas’.